TREATMENT OF INTERSTITIAL PNEUMONITIS DUE TO CYTOMEGALOVIRUS WITH GANCICLOVIR AND INTRAVENOUS IMMUNE GLOBULIN - EXPERIENCE OF EUROPEAN BONE-MARROW TRANSPLANT GROUP

Citation
P. Ljungman et al., TREATMENT OF INTERSTITIAL PNEUMONITIS DUE TO CYTOMEGALOVIRUS WITH GANCICLOVIR AND INTRAVENOUS IMMUNE GLOBULIN - EXPERIENCE OF EUROPEAN BONE-MARROW TRANSPLANT GROUP, Clinical infectious diseases, 14(4), 1992, pp. 831-835
Citations number
13
Language
INGLESE
art.tipo
Article
ISSN journal
1058-4838
Volume
14
Issue
4
Year of publication
1992
Pages
831 - 835
Database
ISI
SICI code
1058-4838(1992)14:4<831:TOIPDT>2.0.ZU;2-2
Abstract
Data on 49 allogenic bone marrow transplant (BMT) recipients who devel oped interstitial pneumonia due to cytomegalovirus (CMV) were collecte d retrospectively. All patients were treated with ganciclovir and high doses of intravenous immune globulin, although types of immune globul ins and schedules of treatment varied. Seventeen (35%) of 49 patients responded to treatment. Thirty days after the diagnosis of interstitia l pneumonia, the survival rate among patients was 31%. CMV was detecte d in 81% of patients on whom autopsies were performed. The survival ra te among patients who received total body irradiation (TBI) was signif icantly lower (11[27%] of 41) than that among patients who did not rec eive TBI (six[75%] of eight; odds ratio = 12.3; P = .009). No other fa ctor, including age, grade of graft-versus-host disease, types and dos e of immune globulin used, or dose of ganciclovir, was correlated to s urvival. These results show that although survival of allogeneic BMT r ecipients with CMV interstitial pneumonia has improved, more than one- half of the patients still died of pneumonia. Thus, both prophylaxis f or and treatment of CMV infection must be improved.